大腸癌の対外診断用スクリーニング検査：グローバル市場分析と予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
3 Disease Overview 27
3.1 Colorectal Cancer 27
3.2 Anatomy and Physiology 27
3.3 Pathophysiology 29
3.3.1 Histology 29
3.3.2 Genetic Basis 30
3.3.3 Etiology of CRC 31
3.4 Clinical Presentation 33
3.4.1 Symptoms 33
3.4.2 Screening Overview 34
3.4.3 Status of National CRC Screening Programs 35
3.4.4 Diagnosis Overview 42
3.4.5 Staging Colorectal Cancer 47
3.5 Clinical Outcomes 50
3.5.1 Treatment Paradigms 50
3.5.2 Treatment Options Overview 52
3.6 Epidemiology 53
3.6.1 Global and Historical Trends 53
3.7 Epidemiology Forecast (2010-2019) 60
3.7.1 Total Incident Cases of Colorectal Cancer 60
3.8 Economic Impact 62
3.8.1 Individual Costs 62
4 Competitive Assessment 65
4.1 Overview 65
4.2 Fecal Occult Blood Tests 65
4.2.1 Guaiac Fecal Occult Blood Stool Tests 65
4.2.2 Lateral Flow Immuno-Fecal Occult Blood Tests 69
4.2.3 Readers 77
4.2.4 Immuno-FOB Test ELISA 80
4.2.5 Immuno-FOB Agglutination Tests 83
4.3 CRC DNA Screening Tests 93
4.3.1 Panel DNA Tests 93
4.3.2 Methylated Gene Testing 103
4.4 Other Biomarker Tests 111
4.4.1 Overview 111
4.4.2 Tumor M2-PK Stool Test/2-in-1 Quick Test 112
4.4.3 Transferrin Assays 115
5 Unmet Needs 117
5.1 False Negative Results 117
5.2 False Positive Results 119
5.3 Sample Type 121
5.4 Screening Compliance 122
5.5 Alternative to Colonoscopy 125
5.6 Accurate Early Staging of Colorectal Cancer 127
5.7 Screening Test Alternatives 128
5.8 Automation 129
6 Pipeline Products 131
6.1 Overview 131
6.2 Pipeline by Phases in Development 131
6.3 Pipeline Product Profiles 133
6.3.1 BST1 CRC Assay 133
6.3.2 Cologic 134
6.3.3 ColoGuard 136
6.3.4 Colon Cancer BEC Test 140
6.3.5 Colon MarCare Plex 141
6.3.6 Colox 144
6.3.7 CRC Bacterial Signature Assay 146
6.3.8 CRC Breath Test 147
6.3.9 Epi proColon 150
6.3.10 ExiQon MicroRNA Test 156
6.3.11 Gemini CRC Biomarker Assay 159
6.3.12 GenomicTree Methylated DNA Test 160
6.3.13 Measure Fecal Occult Blood Test 162
6.3.14 Metabiomics CRC Test 165
6.3.15 MiR-21 Test 167
6.3.16 Oncolite CR 169
6.3.17 PanC-Dx 171
7 Industry Overview 174
7.1 Colorectal Cancer Screening Test Trends 174
7.1.1 US 174
7.1.2 5EU 181
7.1.3 APAC 187
7.1.4 South America (Brazil) 191
7.2 Market Access 192
7.3 Reimbursement Trends 194
7.3.1 US 194
7.3.2 5EU 196
7.3.3 APAC 200
7.3.4 South America (Brazil) 204
7.4 Regulatory Issues and Recalls 205
7.4.1 US 205
7.4.2 5EU 207
7.4.3 APAC Region Regulation 207
7.4.4 Recalls 208
7.5 Mergers and Acquisitions 209
8 Current and Future Players 210
8.1 Overview 210
8.2 Trends in Corporate Strategy 211
8.3 Company Profiles 212
8.3.1 Abbott Molecular 212
8.3.2 Alere 213
8.3.3 Beckman Coulter 216
8.3.4 Biomarcare Technologies 217
8.3.5 Companion Dx 219
8.3.6 Eiken Chemical 220
8.3.7 Epigenomics 224
8.3.8 Exact Sciences 228
8.3.9 ExiQon 233
8.3.10 Fujirebio (Miraca Holdings) 235
8.3.11 GeneNews 238
8.3.12 GenomicTree 239
8.3.13 Immunostics 241
8.3.14 Kyowa Medex 244
8.3.15 MDx Health (was OncoMethylome) 246
8.3.16 Merck Millipore 248
8.3.17 Metabiomics 251
8.3.18 Mode Diagnostics 253
8.3.19 Oncocyte (Bio Time) 255
8.3.20 Quest Diagnostics 257
8.3.21 R-Biopharm 260
8.3.22 Randox Laboratories 263
8.3.23 ScheBo Biotech 265
8.3.24 SciMarket Technologies 268
8.3.25 Siemens Healthcare 269
8.3.26 Signature Diagnostics 272
8.3.27 Sysmex 274
8.3.28 Veda Lab 276
9 Market Drivers, Opportunities and Barriers 278
9.1 Market Drivers 278
9.1.1 Uptake of Pipeline Biomarker Tests 278
9.1.2 Increasing Incidence of Colorectal Cancer and Improvements in Treatment 280
9.1.3 Patient Reluctance to Colonoscopies in Opportunistic CRC Screening 281
9.1.4 Increasing Volume of FOB Tests in Emerging Markets 282
9.1.5 Increased Pressure on Endoscopy Services 282
9.2 Opportunities 283
9.2.1 Blood Tests 283
9.2.2 Increasing CRC Screening Compliance 283
9.2.3 Integration of CRC Screening Tests with Prognostic Tests and Other Screening Programs 285
9.2.4 Emerging Markets 287
9.3 Market Barriers 288
9.3.1 Cultural and Social Resistance to Stool Tests 288
9.3.2 CRC Screening Awareness and Education 288
9.3.3 Reimbursement 289
9.3.4 Local Requirements 290
9.3.5 Test Complexity 293
9.3.6 Patenting Issues 294
10 Country Outlooks & Forecasts 295
10.1 10 Major Markets Overview 295
10.2 US 300
10.2.1 US Market Analysis 300
10.3 France 303
10.3.1 France Market Analysis 303
10.4 Germany 305
10.4.1 Germany Market Analysis 305
10.5 Italy 307
10.5.1 Italy Market Analysis 307
10.6 Spain 309
10.6.1 Spain Analysis 309
10.7 UK 311
10.7.1 UK Market Analysis 311
10.8 Rest of World 314
10.8.1 Japan Market Analysis 314
10.8.2 Brazil Market Analysis 316
10.8.3 China Market Analysis 318
10.8.4 India Market Analysis 320
11 Appendix 322
11.1 Abbreviations 322
11.2 Bibliography 325
11.3 Research Methodology 379
11.3.1 Coverage 379
11.3.2 Secondary Research 380
11.3.3 Forecasting Methodology 380
11.4 Physicians and Specialists Included in this Study 382
11.5 Primary Research 383
11.6 About the Authors 384
11.6.1 Analysts 384
11.6.2 Global Head of Healthcare 385
11.7 About GlobalData 386
11.8 Disclaimer 386